These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

232 related items for PubMed ID: 10759007

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Inactivation of plasminogen activator inhibitor type 1 by activated factor XII plays a role in the enhancement of fibrinolysis by contact factors in-vitro.
    Tanaka A, Suzuki Y, Sugihara K, Kanayama N, Urano T.
    Life Sci; 2009 Jul 31; 85(5-6):220-5. PubMed ID: 19500599
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Mechanism of ancrod anticoagulation. A direct proteolytic effect on fibrin.
    Pizzo SV, Schwartz ML, Hill RL, McKee PA.
    J Clin Invest; 1972 Nov 31; 51(11):2841-50. PubMed ID: 4263497
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Radioimmunoassay of human fibrinopeptide B and kinetics of fibrinopeptide cleavage by different enzymes.
    Bilezikian SB, Nossel HL, Butler VP, Canfield RE.
    J Clin Invest; 1975 Aug 31; 56(2):438-45. PubMed ID: 50328
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Human thrombin and calcium bound factor Xa significantly shorten tPA-induced fibrin clot lysis time via neutralization of plasminogen activator inhibitor type 1 activity.
    Urano T, Nagai N, Matsuura M, Ihara H, Takada Y, Takada A.
    Thromb Haemost; 1998 Jul 31; 80(1):161-6. PubMed ID: 9684803
    [Abstract] [Full Text] [Related]

  • 11. Subunits and susceptibility of fibrins formed from bovine fibrinogen by arvin, reptilase, thrombin and staphylothrombin.
    Zajdel M, Wegrzynowicz Z, Sawecka J, Kopeć M.
    Thromb Res; 1975 Apr 31; 6(4):337-44. PubMed ID: 1169826
    [No Abstract] [Full Text] [Related]

  • 12. Enhanced fibrinolytic potential in mice with combined homozygous deficiency of alpha2-antiplasmin and PAI-1.
    Dewerchin M, Collen D, Lijnen HR.
    Thromb Haemost; 2001 Aug 31; 86(2):640-6. PubMed ID: 11522016
    [Abstract] [Full Text] [Related]

  • 13. Analysis of fibrin formation and proteolysis during intravenous administration of ancrod.
    Dempfle CE, Argiriou S, Kucher K, Müller-Peltzer H, Rübsamen K, Heene DL.
    Blood; 2000 Oct 15; 96(8):2793-802. PubMed ID: 11023513
    [Abstract] [Full Text] [Related]

  • 14. Quantification of the effects of thrombin activatable fibrinolysis inhibitor and alpha2-antiplasmin on fibrinolysis in normal human plasma.
    Nielsen VG, Ellis TC.
    Blood Coagul Fibrinolysis; 2007 Jan 15; 18(1):29-33. PubMed ID: 17179823
    [Abstract] [Full Text] [Related]

  • 15. Novel mechanism to enhance tPA-induced fibrinolysis: effect of limited proteolysis of PAI-1 by neutrophil elastase.
    Urano T, Wu K, Ihara H, Takada Y, Takada A.
    Pol J Pharmacol; 1996 Jan 15; 48(2):209-13. PubMed ID: 9112653
    [Abstract] [Full Text] [Related]

  • 16. Defibrinogenating enzymes.
    Bell WR.
    Drugs; 1997 Jan 15; 54 Suppl 3():18-30; discussion 30-1. PubMed ID: 9360849
    [Abstract] [Full Text] [Related]

  • 17. Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis.
    Jankun J, Aleem AM, Selman SH, Skrzypczak-Jankun E, Lysiak-Szydlowska W, Grafos N, Fryer HJ, Greenfield RS.
    Int J Mol Med; 2007 Nov 15; 20(5):683-7. PubMed ID: 17912461
    [Abstract] [Full Text] [Related]

  • 18. Comparison of the actions of thrombin and the thrombin-like venom enzymes ancrod and batroxobin.
    Aronson DL.
    Thromb Haemost; 1976 Aug 31; 36(1):9-13. PubMed ID: 1036831
    [Abstract] [Full Text] [Related]

  • 19. The effects of green pit viper (Trimeresurus albolabris and Trimeresurus macrops) venom on the fibrinolytic system in human.
    Rojnuckarin P, Intragumtornchai T, Sattapiboon R, Muanpasitporn C, Pakmanee N, Khow O, Swasdikul D.
    Toxicon; 1999 May 31; 37(5):743-55. PubMed ID: 10219986
    [Abstract] [Full Text] [Related]

  • 20. Ancrod: normalization of fibrinolytic enzyme abnormalities in patients with systemic lupus erythematosus and lupus nephritis.
    Glas-Greenwalt P, Kant KS, Dosekun A, Frazier J, Allen C, Pollak VE.
    J Lab Clin Med; 1985 Jan 31; 105(1):99-107. PubMed ID: 3871465
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.